Glecaprevir/pibrentasvir - Abbvie

Drug Profile

Glecaprevir/pibrentasvir - Abbvie

Alternative Names: 2DAA; ABT-493/ABT-530; GLE/PIB; HCV Next Gen; MAVIRET; MAVYRET; Pibrentasvir/glecaprevir

Latest Information Update: 01 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AbbVie; Enanta Pharmaceuticals
  • Developer AbbVie
  • Class Antivirals; Aza compounds; Benzimidazoles; Carbamates; Cyclic ethers; Cyclopentanes; Cyclopropanes; Fluorobenzenes; Piperidines; Pyrrolidines; Quinoxalines; Small molecules
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors; Hepatitis C virus NS3 protein inhibitors; Hepatitis C virus NS4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Hepatitis C

Most Recent Events

  • 30 Nov 2017 Launched for Hepatitis C (Treatment-naive, Treatment-experienced) in Japan (PO)
  • 13 Nov 2017 The Scottish Medicines Consortium accepts glecaprevir/pibrentasivir for routine use by NHS Scotland for the treatment of chronic Hepatitis C
  • 20 Oct 2017 Pooled efficacy and adverse events data from the phase III ENDURANCE-1, ENDURANCE-2, ENDURANCE-3, ENDURANCE-4, EXPEDITION-1, EXPEDITION-4, SURVEYOR-II, and MAGELLAN-1 trials in Hepatitis C presented at the Liver Meeting 2017: 70th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top